Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 425-428

  Gounant, Valérie ^a   Wislez, Marie ^a   Poulot, Virginie ^a   Khalil, Antoine ^a   Lavole, Armelle ^a   Cadranel, Jacques ^a   Milleron, Bernard ^a  

^a HÔPITAL TENON   (France)

Author keywords

Brain metastasis; Epidermal growth factor receptor mutation; Erlotinib; Gefitinib; Lung adenocarcinoma; Non small cell lung cancer; Receptor tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ANAMNESIS; BIOPSY TECHNIQUE; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT OUTCOME;

ADULT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35948985526     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.010     Document Type: Letter

References (9)

1. Popat S., Hughes S., Papadopoulos P., Wilkins A., Moore S., Priest K., et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56 (2007) 135-137
2. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
3. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
4. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
5. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
6. Yokouchi H., Yamazaki K., Kinoshita I., Konishi J., Asahina H., Sukoh N., et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 7 (2007) 51
7. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66 (2006) 7854-7858
8. Van Schaeybroeck S., Kyula J., Kelly D.M., Karaiskou-McCaul A., Stokesberry S.A., Van Cutsem E., et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5 (2006) 1154-1165
9. Gil Delgado M., Spano J.P., and Khayat D. Cetuximab plus irinotecan in refractory colorectal cancer patients. Expert Rev Anticancer Ther 7 (2007) 407-413